# US 10,946,094 B2 · Adenoassociated viral mediated persistant anti-VEGF therapy for ovarian cancer

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 10,946,094 B2
- Document ID: US10946094B2
- Status: Granted
- Kind: B2
- Application number: 15/052,697
- Filed: 2016-02-24
- Published: 2016-08-25
- Granted: 2021-03-16
- Earliest claimed: 2015-02-24
- Assignees: Cornell University
- Applicants: Cornell University
- Inventors: Ronald G. Crystal; Arash Rafii Tabrizi
- Web page: https://patentgrep.com/patent/US10946094B2

## CPC

- A61K 39/39558: {against tumor tissues, cells, antigens}
- A61K 31/337: having four-membered rings, e.g. taxol
- A61K 31/4745: condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines (yohimbine derivatives, vinblastine A61K31/475; ergoline derivatives A61K31/48)
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 35/00: Antineoplastic agents
- C07K 16/22: against growth factors {; against growth regulators}
- C12N 15/8645: {Adeno-associated virus}
- A61K 48/00: Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K 2039/505: {comprising antibodies}
- A61K 2039/54: {characterised by the route of administration}
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C12N 2750/14143: viral genome or elements thereof as genetic vector
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The invention provides a method of treating ovarian cancer in a patient by administering to the patient an adeno-associated virus (AAV) vector encoding an anti-VEGF antibody or antigen binding fragment thereof.

## Claims

### Claim 1

A method of treating ovarian cancer in a patient, the method comprising administering to the patient:
(a) paclitaxel and
(b) a AAVrh10 vector comprising a promoter operably linked to a gene encoding bevacizumab,
wherein the paclitaxel is administered to the patient prior to the administration of the AAVrh10 vector, and
wherein the AAVrh10 vector is administered by intraperitoneal injection to the patient not more than once over a 30 day time period,
thereby treating the ovarian cancer in the patient.

### Claim 2

A method of treating ovarian cancer in a patient, the method comprising administering to the patient:
(a) topetcan and
(b) a AAVrh10 vector comprising a promoter operably linked to a gene encoding bevacizumab,
wherein the topetcan is administered to the patient prior to the administration of the AAVrh10 vector, and
wherein the AAVrh10 vector is administered by intraperitoneal injection to the patient not more than once over a 30 day time period,
thereby treating the ovarian cancer in the patient.